Value
3.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 3.0 |
- ▸Expensive valuation
KYMR · Why this verdict
Why Kymera Therapeutics (KYMR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Kymera Therapeutics shows strong top-line momentum at 56% year-over-year revenue growth, but persistent and deep cash consumption at 271% of revenue, a quality score of 1.6 out of 10 well below the 4.0 minimum floor, three of the four most recent quarters delivering results short of expectations, and heavy short interest at 16% with a put/call ratio above 2.2 together make this an unsuitable candidate for new entry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company consumes cash at a rate equal to 271% of revenue, and profitability metrics across return on assets, operating margin, and competitive positioning all score near zero, placing the overall quality score at 1.6 out of 10—well below the 4.0 minimum threshold required to justify a position. Quality breakdown | Quality recovers above 4.0 only if free cash flow turns positive and operating margins show material improvement for at least 2 consecutive quarters. | →Stable |
| CounterClinical-stage biotechs are expected to burn cash ahead of commercial launch; the elevated spend could reflect deliberate pipeline investment, and if lead programs advance toward approval, quality metrics will improve before the stock fully prices in the outcome. | ||
Of the four most recent reported quarters, three ended with earnings results worse than consensus estimates, with average losses per share exceeding expectations by a wide margin in two of those three quarters; only the single most recent quarter produced a beat. Earnings | The miss pattern is falsified if EPS surprises turn consistently positive—exceeding 0%—for 3 consecutive quarters. | →Stable |
| CounterThe most recent quarter delivered a 17% positive earnings surprise against expectations, suggesting the miss streak may be inflecting; if that execution discipline holds, the execution risk case weakens materially. | ||
Short interest represents 16% of the float and the put-to-call ratio sits above 2.2, indicating that a substantial portion of market participants are positioned for the stock to decline—creating meaningful technical pressure that can amplify any negative news. Risk breakdown | Short interest falling below 10% of float and the put/call ratio compressing below 1.0 would signal that the bearish positioning is unwinding. | →Stable |
| CounterElevated short interest creates the conditions for a short squeeze on positive clinical news; if data surprises favorably, forced covering could drive a disproportionately large upside move that punishes latecomers to the bear thesis. | ||
A recent officer departure or appointment was flagged as a governance concern, introducing near-term uncertainty about strategic continuity at a stage when leadership decisions directly affect clinical program prioritization and capital allocation. Gates warning | The governance risk diminishes if the company delivers 2 consecutive earnings quarters with EPS surprises exceeding 0% and no additional officer-change filings during that period. | →Stable |
| CounterLeadership transitions at clinical-stage biotechs are common and often planned well in advance; the incoming officer may bring specific expertise that strengthens the development pipeline rather than disrupting it. | ||
The company consumes cash at a rate equal to 271% of revenue, and profitability metrics across return on assets, operating margin, and competitive positioning all score near zero, placing the overall quality score at 1.6 out of 10—well below the 4.0 minimum threshold required to justify a position.
→StableQuality breakdown
- Expectation
- Quality recovers above 4.0 only if free cash flow turns positive and operating margins show material improvement for at least 2 consecutive quarters.
CounterClinical-stage biotechs are expected to burn cash ahead of commercial launch; the elevated spend could reflect deliberate pipeline investment, and if lead programs advance toward approval, quality metrics will improve before the stock fully prices in the outcome.
Of the four most recent reported quarters, three ended with earnings results worse than consensus estimates, with average losses per share exceeding expectations by a wide margin in two of those three quarters; only the single most recent quarter produced a beat.
→StableEarnings
- Expectation
- The miss pattern is falsified if EPS surprises turn consistently positive—exceeding 0%—for 3 consecutive quarters.
CounterThe most recent quarter delivered a 17% positive earnings surprise against expectations, suggesting the miss streak may be inflecting; if that execution discipline holds, the execution risk case weakens materially.
Short interest represents 16% of the float and the put-to-call ratio sits above 2.2, indicating that a substantial portion of market participants are positioned for the stock to decline—creating meaningful technical pressure that can amplify any negative news.
→StableRisk breakdown
- Expectation
- Short interest falling below 10% of float and the put/call ratio compressing below 1.0 would signal that the bearish positioning is unwinding.
CounterElevated short interest creates the conditions for a short squeeze on positive clinical news; if data surprises favorably, forced covering could drive a disproportionately large upside move that punishes latecomers to the bear thesis.
A recent officer departure or appointment was flagged as a governance concern, introducing near-term uncertainty about strategic continuity at a stage when leadership decisions directly affect clinical program prioritization and capital allocation.
→StableGates warning
- Expectation
- The governance risk diminishes if the company delivers 2 consecutive earnings quarters with EPS surprises exceeding 0% and no additional officer-change filings during that period.
CounterLeadership transitions at clinical-stage biotechs are common and often planned well in advance; the incoming officer may bring specific expertise that strengthens the development pipeline rather than disrupting it.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.2 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -271% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 56% YoY
Momentum
8.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 10.0 |
| vol acceleration | 8.0 |
- ▸Overbought (RSI 95)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
- ▸Volume surge (2.0x avg) on up move
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.8 |
| Analyst rating | 9.0 |
| Price target | 4.9 |
- ▸LLM news sentiment: +0.35 (n=10)
Insider
3.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Heavy insider selling — $58,864,127 (0.717% of mkt cap)
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.6 |
| growth rank | 6.6 |
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 1.6 |
| 52w position | 8.5 |
| gap | 3.0 |
- ▸Extreme gap up (8.9%) - may pull back
Risk (lower is worse)
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.9 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 2.8 |
| max pain risk | 3.0 |
| beta | 3.2 |
| debt equity | 0.0 |
- ▸High short interest justified: 16%
- ▸Elevated put/call: 9.58
- ▸High IV: 63%
- ▸Above max pain $65
Catalyst
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 8.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:8.4>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:46d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.7=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.72
Upside
-10.7%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 2.03>1.3
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.7=NEGATIVE.
The strongest dimensions are Growth at 10.0, Momentum at 8.4, and Sentiment at 7.1; the weakest are Risk (lower is worse) at 1.4, Quality at 1.6, and Insider at 3.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.72 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company consumes cash at a rate equal to 271% of revenue, and profitability metrics across return on assets, operating margin, and competitive positioning all score near zero, placing the overall quality score at 1.6 out of 10—well below the 4.0 minimum threshold required to justify a position.
Trip ifFree cash flow turns positive (FCF exceeds 0% of revenue) for 2 consecutive quarters.
- P2Of the four most recent reported quarters, three ended with earnings results worse than consensus estimates, with average losses per share exceeding expectations by a wide margin in two of those three quarters; only the single most recent quarter produced a beat.
Trip ifEPS surprise exceeds 0% for 3 consecutive quarters.
- P3Short interest represents 16% of the float and the put-to-call ratio sits above 2.2, indicating that a substantial portion of market participants are positioned for the stock to decline—creating meaningful technical pressure that can amplify any negative news.
Trip ifShort interest falls below 10% of float.
- P4A recent officer departure or appointment was flagged as a governance concern, introducing near-term uncertainty about strategic continuity at a stage when leadership decisions directly affect clinical program prioritization and capital allocation.
Trip ifCompany reports 2 consecutive quarters with EPS surprise above 0% and zero additional officer-change 8-K filings during that period.